Trial Profile
ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Alicaforsen (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 07 Jan 2016 New trial record